Under a tenth of individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the WHO as it publishes its first advice on the drugs.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for increased and just access to these injectable treatments.
Based on estimates, more than two billion are projected to be obese by 2030 unless action is taken.
"The new guidance recognises that obesity is a lifelong illness that can be treated with comprehensive and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key hurdles to widespread availability to the injections that can aid individuals in losing considerable body mass, explains the organization.
Weight-Loss Drug Shortage
Even in the present most favorable outlook, the supply of these medications could only cover approximately 100 million people – less than 10% of those who need them, per the health organization.
The advice calls on nations and manufacturers to expand availability, by approaches including patent sharing.
Exclusive production rights on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Obesity Jabs Work
These medications replicate a biological compound to reduce digestion speed, reduce hunger and boost satiety so individuals consume fewer calories.
Patients commonly begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Studies suggests users may see weight return a year later of stopping the drug, because their usual food cravings come back.
To be carrying excess weight raises your chance for developing medical conditions, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns people in all nations and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
